Posted in bill parish, Drug companies, Politics, Uncategorized, World News, tagged 10K, canada, carried interest, Cash flows, Caterpillar, Donald Trump, DRI Capital, Drug companies, Drug Royalty, Drugs, Eli Lilly, Healthcare, Inversions, Investors, Irish, Johnson and Johnson, London stock exchange, management fee, Merck, Mitch McConnell, New York Times, Obamacare, Pablo Legorreta, Patients, Pfizer, Private Equity, Product specific inversion, public pensions, Royalty, Royalty Interests, Royalty Pharma, sec, SEC 10Q, taxes, Trumpcare on July 19, 2017|
When evaluating health care investments it is important to analyze the structure of leading drug and medical equipment companies. A close look indeed reveals a derivative driven system in which private equity and hedge funds increase demand for drug payments by purchasing the rights to the cash flows from key drugs. Patients are indeed unaware that many of the drugs they consume are now owned in part by private equity investors.
